The MHRA have made the following statement in response to the research paper published in the Lancet concerning non-steroidal anti-inflammatory drugs (NSAIDs) such as Ibuprofen and Diclofenac and the risks of cardiovascular problems:
Dr Sarah Branch, the MHRA’s Deputy Director for the Vigilance and Risk Management and of Medicines, said: “These findings in the Lancet are not new and confirm the conclusions reached in October 2012 by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).
“Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and diclofenac are effective painkillers. A small increase in cardiovascular risk is associated with long-term use of ibuprofen and diclofenac at high doses. The short term use of ibuprofen at doses available without a prescription has not been associated with an increased risk. The MHRA’s current treatment advice for all NSAIDs is for people to use the lowest effective dose, for the shortest duration necessary to control symptoms. If people have any questions about their treatment they should contact their pharmacist or doctor.”